charting our path

The pharmaceutical space is dotted with stars that are primed to be reignited to renewed brilliance.

envisioning better

Propella selects new drug opportunities in the context of unmet patient needs. Our proprietary approach to the design and development of improved therapies aims to bring improved choices to patients and healthcare professionals underserved by current standards of care.

bright light thinking

We accomplish our mission by thoroughly investigating and identifying existing standards of oncology care that suffer from known limitations such as efficacy concerns due to inadequate target exposures and safety concerns due to overexposure to non-target tissues. Using our medicinal chemistry expertise, we design novel product candidates that utilize lymphatic targeting and focus on a well-defined biological target. Once a candidate is identified, we assess all aspects of its profile, including the applicability of lymphatic targeting for the biological target of interest, the indication, unmet medical need, barriers to entry, and commercial opportunities. We then engage stakeholders such as patients, doctors, payers and other experts for their insights and validation of the novel therapeutic approach. Ultimately, our approach yields a best-in-class candidate therapy with a profile that addresses one or more significant unmet needs in the treatment landscape.

Click image to enlarge.

The lymphatic system is a vast network of vessels, lymph nodes and organs that connects the circulatory and immune systems. Lymphatic targeting employs the lymphatic system to preferentially deliver high concentrations of drug to target tissues. Lymphatic targeting has shown promise across different routes of administration, including by intramuscular injection and oral administration. Advantages of lymphatic targeting include:

  • Increased bioavailability and pharmacodynamic activity
  • Creation of secondary drug depots in key target tissues including lymph nodes and bone metastatic sites
  • Reduced drug delivery to organs causing toxicity (e.g., liver, CNS)
  • Improved safety margin/therapeutic index

The mechanism of action of and applicability of our products to oncologic diseases have been well studied previously. Our drug product candidates are protected by issued composition of matter patents owned by us, which provides for a risk-mitigated development and commercialization path. We believe making new drugs that are more effective, tolerable, and convenient for patients is both smart science and great business. Brighter treatments lay ahead.